Your browser doesn't support javascript.
loading
Exon-Skipping-Based Subtyping of Colorectal Cancers.
Ambeskovic, Aslihan; McCall, Matthew N; Woodsmith, Jonathan; Juhl, Hartmut; Land, Hartmut.
Afiliação
  • Ambeskovic A; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, New York.
  • McCall MN; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, New York; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York; Wilmot Cancer institute, University of Rochester Medical Center, Rochester, New York.
  • Woodsmith J; Indivumed GmbH, Hamburg, Germany.
  • Juhl H; Indivumed GmbH, Hamburg, Germany.
  • Land H; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, New York; Wilmot Cancer institute, University of Rochester Medical Center, Rochester, New York. Electronic address: Land@URMC.Rochester.edu.
Gastroenterology ; 2024 Aug 23.
Article em En | MEDLINE | ID: mdl-39181169
ABSTRACT
BACKGROUND &

AIMS:

The identification of colorectal cancer (CRC) molecular subtypes has prognostic and potentially diagnostic value for patients, yet reliable subtyping remains unavailable in the clinic. The current consensus molecular subtype (CMS) classification in CRCs is based on complex RNA expression patterns quantified at the gene level. The clinical application of these methods, however, is challenging due to high uncertainty of single-sample classification and associated costs. Alternative splicing, which strongly contributes to transcriptome diversity, has rarely been used for tissue type classification. Here, we present an AS-based CRC subtyping framework sensitive to differential exon use that can be adapted for clinical application.

METHODS:

Unsupervised clustering was used to measure the strength of association between different categories of alternative splicing and CMS. To build a classifier, the ground truth for CMS labels was derived from expression data quantified at the gene level. Feature selection was achieved through bootstrapping and L1-penalized estimation. The resulting feature space was used to construct a subtype prediction framework applicable to single and multiple samples. The performance of the models was evaluated on unseen CRCs from 2 independent sources (Indivumed, n = 129; The Cancer Genome Atlas, n = 99).

RESULTS:

We developed a CRC subtype identifier based on 29 exon-skipping events that accurately classifies unseen tumors and enables more precise differentiation of subtypes characterized by distinct biological and prognostic features as compared to classifiers based on gene expression.

CONCLUSIONS:

Here, we demonstrate that a small number of exon-skipping events can reliably classify CRC subtypes using individual patient specimens in a manner suitable to clinical application.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article